Levonorgestrel IUD Potentially Cost-Effective in Obese Women

Share this content:
Levonorgestrel IUD Potentially Cost-Effective in Obese Women
Levonorgestrel IUD Potentially Cost-Effective in Obese Women

MONDAY, Sept. 12, 2016 (HealthDay News) -- For obese women, the levonorgestrel intrauterine device (IUD) could be cost-effective for preventing endometrial cancer deaths, according to a study published in the October issue of Obstetrics & Gynecology.

Joseph A. Dottino, M.D., M.P.H., from the Duke University Medical Center in Durham, N.C., and colleagues used a modified Markov model to compare IUD placement at age 50 with usual care among women with a BMI ≥40 or ≥30 kg/m². The authors incorporated the effect of obesity on incidence and survival. The IUD was assumed to confer a 50 percent reduction in the incidence of endometrial cancer over five years; costs of IUD and cancer care were included in the analyses.

The researchers found that the IUD strategy was costlier and more effective than usual care for a 50-year-old with BMI ≥40 kg/m², with a cost-effectiveness ratio of $74,707 per year of life saved. Assuming the protective effect of the levonorgestrel IUD was 10 years, the incremental cost-effectiveness ratio would decrease to $37,858 per life-year saved. In women with BMIs of ≥40 kg/m² or costs less than $500, a levonorgestrel IUD that reduces cancer incidence by at least 68 percent would be cost-effective. The incremental cost-effectiveness ratio of IUD strategy was $137,223 per life-year saved compared with usual care for women with BMI ≥30 kg/m².

"The levonorgestrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial cancer in obese women," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA OKs Drug for Hemophilia A With Factor VIII Inhibitors

FDA OKs Drug for Hemophilia A With Factor ...

Weekly prophylactic treatment associated with substantial decrease in bleeding episodes

Risk of Falls Up With Mild, Moderate Diabetic Retinopathy

Risk of Falls Up With Mild, Moderate Diabetic ...

And perceived barriers to diabetes self-management are associated with severity of diabetic retinopathy

AMD Risk Has Dropped By Birth Cohort Throughout 20th Century

AMD Risk Has Dropped By Birth Cohort Throughout ...

Generational association remains significant after adjustment for age, sex, other confounders

is free, fast, and customized just for you!

Already a member?

Sign In Now »